POS0731 IDENTIFICATION OF AUTOANTIBODY SIGNATURES AND BIOMARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) USING HIGH-THROUGHPUT PROTEOMIC MICROARRAYS
Background:High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification of novel serum autoantibodies and their signatures that correlate with and potentially predict disease activity, flare and damage in SLE. Her...
Uložené v:
| Vydané v: | Annals of the rheumatic diseases Ročník 83; číslo Suppl 1; s. 997 - 998 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Kidlington
BMJ Publishing Group Ltd and European League Against Rheumatism
01.06.2024
Elsevier B.V Elsevier Limited |
| Predmet: | |
| ISSN: | 0003-4967, 1468-2060 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background:High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification of novel serum autoantibodies and their signatures that correlate with and potentially predict disease activity, flare and damage in SLE. Herein, we present extended analyses of our original investigation [1] into novel autoantibodies in predicting disease activity and flares in patients with SLE.Objectives:To validate our preliminarily discovered putative autoantibodies in a larger cohort of SLE patients and correlate these autoantibodies with clinical manifestations, disease activity and damage longitudinally.Methods:Serum autoantibody profiling of 60 SLE patients was compared with 15 healthy subjects using the Sengenics I-Ome high-throughput proteomic microarray that can identify over 1,600 proteins in the sera. We conducted linear modeling analyses to identify novel autoantibodies that were significantly altered in SLE patients compared with healthy subjects. We also determined whether these autoantibodies could predict the baseline risk of disease flares, organ involvement, and SLEDAI-2K at 3 and 6 months from baseline.Results:Bioinformatics analyses identified several autoantibodies weighted by their occurrence frequencies in flares, organ involvement, and correlation with disease activity status (Figure 1). Compared to healthy subjects, autoantibodies against CARD9 (p=0.019), PAX5 (p= 0.018), HMG20B (p=0.05), and ZNF276(p=0.019) were associated with baseline and subsequent risk of overall disease flares, renal involvement, and vasculitis. CARD9 is an adapter of C-type lectin receptors with a caspase-recruitment domain that recruits BCL10 (a regulator of apoptosis and NFkB/MAPK-mediated signaling). PAX5 is a transcription factor that regulates B-cell responses. HMG20B facilitates DNA binding,and positively regulates neuronal differentiation. ZNF276 facilitates dsDNA binding and regulates transcription. Anti-SRPK1,regulates splicing, was predictive of CNS involvement. The serum levels of HNRNPUL1(p=0.049), ZNF323(p=0.011), and HMG20B were significantly associated with higher SLEDAI-2K at 3 and 6 months. Additionally, HNRNPA2/B1, a nuclear DNA sensor that amplifies interferon-1 responses, correlated with higher SLEDAI-2K at 6 months (p= 0.0035). The five most common autoantibody signatures in extended analysis targeted SSB, CCNB1,TROVE2, DEK, and HNRNPA2B1, which were increased in SLE patients compared to healthy subjects.Figure 1.Violin plots of representative antigens with p-value < 0.05 from Linear Modelling AnalysisAbbreviations:CARD9: Caspase recruitment domain-containing protein 9 is an adaptor protein encoded by the CARD9 gene, mediates signals from pattern recognition receptors, and regulates inflammation.PAX5: Paired box protein -5 is a key regulator in B cell development at different stages, involved in B-cell signaling and adhesion and migration of B lymphocytes.HMG20B: High Mobility Group 20B is a Protein Coding gene that enables DNA binding and regulates gene expression and neuronal differentiation.ZNF276: Zinc Finger Protein 276 is a Protein Coding gene that enables sequence-specific double-stranded DNA binding activity.SRPK1: Serine/Arginine-Rich Protein-Specific Kinase 1 protein regulates the expression of apoptosis-related genes.Y denotes presence of autoantigen in serum samples.N denotes absence of autoantigens in serum samples.Conclusion:Using high-throughput proteomic microarray, a number of novel autoantibodies and their signatures related to disease activity and specific organ involvement were identified in SLE patients. Further validations of the pathophysiology of these novel autoantibodies detected in SLE patients with larger cohorts internationally are required.REFERENCES:[1] Mak A, Kow NY, Ismail NH, Anuar ND, Rutt NH, Cho J, et al. Detection of putative autoantibodies in systemic lupus erythematous using a novel native-conformation protein microarray platform. Lupus. 2020;29(14):1948-54.Acknowledgements:NIL.Disclosure of Interests:None declared. |
|---|---|
| AbstractList | Background:High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification of novel serum autoantibodies and their signatures that correlate with and potentially predict disease activity, flare and damage in SLE. Herein, we present extended analyses of our original investigation [1] into novel autoantibodies in predicting disease activity and flares in patients with SLE.Objectives:To validate our preliminarily discovered putative autoantibodies in a larger cohort of SLE patients and correlate these autoantibodies with clinical manifestations, disease activity and damage longitudinally.Methods:Serum autoantibody profiling of 60 SLE patients was compared with 15 healthy subjects using the Sengenics I-Ome high-throughput proteomic microarray that can identify over 1,600 proteins in the sera. We conducted linear modeling analyses to identify novel autoantibodies that were significantly altered in SLE patients compared with healthy subjects. We also determined whether these autoantibodies could predict the baseline risk of disease flares, organ involvement, and SLEDAI-2K at 3 and 6 months from baseline.Results:Bioinformatics analyses identified several autoantibodies weighted by their occurrence frequencies in flares, organ involvement, and correlation with disease activity status (Figure 1). Compared to healthy subjects, autoantibodies against CARD9 (p=0.019), PAX5 (p= 0.018), HMG20B (p=0.05), and ZNF276(p=0.019) were associated with baseline and subsequent risk of overall disease flares, renal involvement, and vasculitis. CARD9 is an adapter of C-type lectin receptors with a caspase-recruitment domain that recruits BCL10 (a regulator of apoptosis and NFkB/MAPK-mediated signaling). PAX5 is a transcription factor that regulates B-cell responses. HMG20B facilitates DNA binding,and positively regulates neuronal differentiation. ZNF276 facilitates dsDNA binding and regulates transcription. Anti-SRPK1,regulates splicing, was predictive of CNS involvement. The serum levels of HNRNPUL1(p=0.049), ZNF323(p=0.011), and HMG20B were significantly associated with higher SLEDAI-2K at 3 and 6 months. Additionally, HNRNPA2/B1, a nuclear DNA sensor that amplifies interferon-1 responses, correlated with higher SLEDAI-2K at 6 months (p= 0.0035). The five most common autoantibody signatures in extended analysis targeted SSB, CCNB1,TROVE2, DEK, and HNRNPA2B1, which were increased in SLE patients compared to healthy subjects.Figure 1.Violin plots of representative antigens with p-value < 0.05 from Linear Modelling AnalysisAbbreviations:CARD9: Caspase recruitment domain-containing protein 9 is an adaptor protein encoded by the CARD9 gene, mediates signals from pattern recognition receptors, and regulates inflammation.PAX5: Paired box protein -5 is a key regulator in B cell development at different stages, involved in B-cell signaling and adhesion and migration of B lymphocytes.HMG20B: High Mobility Group 20B is a Protein Coding gene that enables DNA binding and regulates gene expression and neuronal differentiation.ZNF276: Zinc Finger Protein 276 is a Protein Coding gene that enables sequence-specific double-stranded DNA binding activity.SRPK1: Serine/Arginine-Rich Protein-Specific Kinase 1 protein regulates the expression of apoptosis-related genes.Y denotes presence of autoantigen in serum samples.N denotes absence of autoantigens in serum samples.Conclusion:Using high-throughput proteomic microarray, a number of novel autoantibodies and their signatures related to disease activity and specific organ involvement were identified in SLE patients. Further validations of the pathophysiology of these novel autoantibodies detected in SLE patients with larger cohorts internationally are required.REFERENCES:[1] Mak A, Kow NY, Ismail NH, Anuar ND, Rutt NH, Cho J, et al. Detection of putative autoantibodies in systemic lupus erythematous using a novel native-conformation protein microarray platform. Lupus. 2020;29(14):1948-54.Acknowledgements:NIL.Disclosure of Interests:None declared. Background:High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification of novel serum autoantibodies and their signatures that correlate with and potentially predict disease activity, flare and damage in SLE. Herein, we present extended analyses of our original investigation [1] into novel autoantibodies in predicting disease activity and flares in patients with SLE.Objectives:To validate our preliminarily discovered putative autoantibodies in a larger cohort of SLE patients and correlate these autoantibodies with clinical manifestations, disease activity and damage longitudinally.Methods:Serum autoantibody profiling of 60 SLE patients was compared with 15 healthy subjects using the Sengenics I-Ome high-throughput proteomic microarray that can identify over 1,600 proteins in the sera. We conducted linear modeling analyses to identify novel autoantibodies that were significantly altered in SLE patients compared with healthy subjects. We also determined whether these autoantibodies could predict the baseline risk of disease flares, organ involvement, and SLEDAI-2K at 3 and 6 months from baseline.Results:Bioinformatics analyses identified several autoantibodies weighted by their occurrence frequencies in flares, organ involvement, and correlation with disease activity status (Figure 1). Compared to healthy subjects, autoantibodies against CARD9 (p=0.019), PAX5 (p= 0.018), HMG20B (p=0.05), and ZNF276(p=0.019) were associated with baseline and subsequent risk of overall disease flares, renal involvement, and vasculitis. CARD9 is an adapter of C-type lectin receptors with a caspase-recruitment domain that recruits BCL10 (a regulator of apoptosis and NFkB/MAPK-mediated signaling). PAX5 is a transcription factor that regulates B-cell responses. HMG20B facilitates DNA binding,and positively regulates neuronal differentiation. ZNF276 facilitates dsDNA binding and regulates transcription. Anti-SRPK1,regulates splicing, was predictive of CNS involvement. The serum levels of HNRNPUL1(p=0.049), ZNF323(p=0.011), and HMG20B were significantly associated with higher SLEDAI-2K at 3 and 6 months. Additionally, HNRNPA2/B1, a nuclear DNA sensor that amplifies interferon-1 responses, correlated with higher SLEDAI-2K at 6 months (p= 0.0035). The five most common autoantibody signatures in extended analysis targeted SSB, CCNB1,TROVE2, DEK, and HNRNPA2B1, which were increased in SLE patients compared to healthy subjects.Figure 1.Violin plots of representative antigens with p-value < 0.05 from Linear Modelling AnalysisAbbreviations:CARD9: Caspase recruitment domain-containing protein 9 is an adaptor protein encoded by the CARD9 gene, mediates signals from pattern recognition receptors, and regulates inflammation.PAX5: Paired box protein -5 is a key regulator in B cell development at different stages, involved in B-cell signaling and adhesion and migration of B lymphocytes.HMG20B: High Mobility Group 20B is a Protein Coding gene that enables DNA binding and regulates gene expression and neuronal differentiation.ZNF276: Zinc Finger Protein 276 is a Protein Coding gene that enables sequence-specific double-stranded DNA binding activity.SRPK1: Serine/Arginine-Rich Protein-Specific Kinase 1 protein regulates the expression of apoptosis-related genes.Y denotes presence of autoantigen in serum samples.N denotes absence of autoantigens in serum samples.[Figure omitted. See PDF]Conclusion:Using high-throughput proteomic microarray, a number of novel autoantibodies and their signatures related to disease activity and specific organ involvement were identified in SLE patients. Further validations of the pathophysiology of these novel autoantibodies detected in SLE patients with larger cohorts internationally are required.REFERENCES:[1] Mak A, Kow NY, Ismail NH, Anuar ND, Rutt NH, Cho J, et al. Detection of putative autoantibodies in systemic lupus erythematous using a novel native-conformation protein microarray platform. Lupus. 2020;29(14):1948-54.Acknowledgements:NIL.Disclosure of Interests:None declared. High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification of novel serum autoantibodies and their signatures that correlate with and potentially predict disease activity, flare and damage in SLE. Herein, we present extended analyses of our original investigation [1] into novel autoantibodies in predicting disease activity and flares in patients with SLE. To validate our preliminarily discovered putative autoantibodies in a larger cohort of SLE patients and correlate these autoantibodies with clinical manifestations, disease activity and damage longitudinally. Serum autoantibody profiling of 60 SLE patients was compared with 15 healthy subjects using the Sengenics I-Ome high-throughput proteomic microarray that can identify over 1,600 proteins in the sera. We conducted linear modeling analyses to identify novel autoantibodies that were significantly altered in SLE patients compared with healthy subjects. We also determined whether these autoantibodies could predict the baseline risk of disease flares, organ involvement, and SLEDAI-2K at 3 and 6 months from baseline. Bioinformatics analyses identified several autoantibodies weighted by their occurrence frequencies in flares, organ involvement, and correlation with disease activity status (Figure 1). Compared to healthy subjects, autoantibodies against CARD9 (p=0.019), PAX5 (p= 0.018), HMG20B (p=0.05), and ZNF276(p=0.019) were associated with baseline and subsequent risk of overall disease flares, renal involvement, and vasculitis. CARD9 is an adapter of C-type lectin receptors with a caspase-recruitment domain that recruits BCL10 (a regulator of apoptosis and NFkB/MAPK-mediated signaling). PAX5 is a transcription factor that regulates B-cell responses. HMG20B facilitates DNA binding,and positively regulates neuronal differentiation. ZNF276 facilitates dsDNA binding and regulates transcription. Anti-SRPK1,regulates splicing, was predictive of CNS involvement. The serum levels of HNRNPUL1(p=0.049), ZNF323(p=0.011), and HMG20B were significantly associated with higher SLEDAI-2K at 3 and 6 months. Additionally, HNRNPA2/B1, a nuclear DNA sensor that amplifies interferon-1 responses, correlated with higher SLEDAI-2K at 6 months (p= 0.0035). The five most common autoantibody signatures in extended analysis targeted SSB, CCNB1,TROVE2, DEK, and HNRNPA2B1, which were increased in SLE patients compared to healthy subjects. Using high-throughput proteomic microarray, a number of novel autoantibodies and their signatures related to disease activity and specific organ involvement were identified in SLE patients. Further validations of the pathophysiology of these novel autoantibodies detected in SLE patients with larger cohorts internationally are required. [1] Mak A, Kow NY, Ismail NH, Anuar ND, Rutt NH, Cho J, et al. Detection of putative autoantibodies in systemic lupus erythematous using a novel native-conformation protein microarray platform. Lupus. 2020;29(14):1948-54. NIL. None declared. [Display omitted] |
| Author | Cho, J. Nasir, N. Mak, A. |
| Author_xml | – sequence: 1 givenname: A. surname: Mak fullname: Mak, A. organization: National University Hospital, Singapore, Division of Rheumatology, Department of Medicine, Singapore, Singapore – sequence: 2 givenname: N. surname: Nasir fullname: Nasir, N. organization: National University Hospital, Singapore, Division of Rheumatology, Department of Medicine, Singapore, Singapore – sequence: 3 givenname: J. surname: Cho fullname: Cho, J. organization: National University Hospital, Singapore, Division of Rheumatology, Department of Medicine, Singapore, Singapore |
| BookMark | eNqNkc-O0zAQxi20SHQX3sHSXuCQxY7zxzl6WzexaOModkA5WXXjiFa76ZJsOXPhlXggngSHIsGRw2g0o2--mdHvGlwNp8EBcIvRHcYkeb8bhvGzOz92hykIURgF7vywG-8iFJMXYIGjhPp2gq7AAiFEgihL0lfgepqOvkQU0wX4UUmFUoJ_fvsuVrzUYi2WTAtZQrmGrNGS-d69XLVQibxkuqm5gqxcwXsht6z-wGs1K1dCcaY4ZEstPgrdQlHCyvt4RwU_CV1A1SrNt2IJN03VKMjrVhd8y7RUvnqrNvwdbJQoc1iIvAh0UcsmL6pGw6qWmst50kctWV2zVr0GL_vdw-Te_Mk3oFlzvSyCjcz9A5vAYkLjoMtIRwi2_tfe7igiKHNpH2dZH_W0JySyfUwtRVmCne3pPrQd7Tsbotgi4nBEbsDtxfdpPH05u-nZHE_ncfArDcEIZWFKw9ir-EXl_ClfD2400_7ghr3rDqPbP5vudDAYmRmZ-QeZmZGZ38jMjMz7pBcf-3j8u-h_Jn8BrTaZWQ |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. – notice: 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. |
| DBID | K9. |
| DOI | 10.1136/annrheumdis-2024-eular.4053 |
| DatabaseName | ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitle | ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-2060 |
| EndPage | 998 |
| ExternalDocumentID | S0003496724163819 annrheumdis |
| GroupedDBID | --- .55 .GJ .VT 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP 0R~ AAFWJ AALRI PHGZM PJZUB PPXIY PQGLB PUEGO K9. |
| ID | FETCH-LOGICAL-b1385-d93d331b081fba80309e7f599f4f8f334bf58b80961ebf8c2bd8fdb205b03e143 |
| ISSN | 0003-4967 |
| IngestDate | Tue Oct 07 07:15:49 EDT 2025 Sat Aug 30 17:13:06 EDT 2025 Thu Apr 24 22:50:04 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 1 |
| Keywords | omics Biomarkers, Protein microarrays Autoantibodies |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-b1385-d93d331b081fba80309e7f599f4f8f334bf58b80961ebf8c2bd8fdb205b03e143 |
| Notes | EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| PQID | 3100927825 |
| PQPubID | 2041045 |
| PageCount | 2 |
| ParticipantIDs | proquest_journals_3100927825 elsevier_sciencedirect_doi_10_1136_annrheumdis_2024_eular_4053 bmj_journals_10_1136_annrheumdis_2024_eular_4053 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-June June 2024 20240601 |
| PublicationDateYYYYMMDD | 2024-06-01 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024-June |
| PublicationDecade | 2020 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington |
| PublicationTitle | Annals of the rheumatic diseases |
| PublicationTitleAbbrev | Ann Rheum Dis |
| PublicationYear | 2024 |
| Publisher | BMJ Publishing Group Ltd and European League Against Rheumatism Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: BMJ Publishing Group Ltd and European League Against Rheumatism – name: Elsevier B.V – name: Elsevier Limited |
| SSID | ssj0000818 |
| Score | 2.448534 |
| Snippet | Background:High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification... High-throughput protein microarrays are increasingly employed to investigate disease-related autoantibodies in patients with SLE for identification of novel... |
| SourceID | proquest elsevier bmj |
| SourceType | Aggregation Database Publisher |
| StartPage | 997 |
| SubjectTerms | Adaptor proteins Amino acid sequence Apoptosis Autoantibodies Autoantigens Bcl-10 protein Bioinformatics Biomarkers, Protein microarrays Caspase Cell differentiation Cell signaling Deoxyribonucleic acid DNA DNA microarrays Gene expression Kinases Leukocyte migration Lupus Lymphocytes B MAP kinase Neural coding Nucleotide sequence omics Pattern recognition receptors Protein structure Proteins Risk assessment Scientific Abstracts Systemic lupus erythematosus Vasculitis Zinc finger proteins |
| Title | POS0731 IDENTIFICATION OF AUTOANTIBODY SIGNATURES AND BIOMARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) USING HIGH-THROUGHPUT PROTEOMIC MICROARRAYS |
| URI | https://ard.bmj.com/content/83/Suppl_1/997.2.full https://dx.doi.org/10.1136/annrheumdis-2024-eular.4053 https://www.proquest.com/docview/3100927825 |
| Volume | 83 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: M7P dateStart: 19390101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: M0R dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: 7X7 dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: BENPR dateStart: 19390101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: M2P dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbKhiZuEL_aYEyW4AIUpaRxUjs3SCnLmog1ieIUtVdR0iZiCArqfrRLbngl3oAX4Uk4dpym3SQ0hLioVVmWneT7fHxsnx-EXhQGsfu53ddNx8p1q2ClXlS2qROSU6dfGTM7l3Fmj2kYssnEiTudn40vzMUnuliwy0vn63-FGuoAbOE6-xdwrzqFCvgPoEMJsEN5I-DjiMOE6ikrBmYHh16YBkfKY1hY-cCDRi7UDaLDqcaDYW37wGWkqUEQjdzknXA8gJaHAfdc7mnC1OR9kE61INRi6Ad65LD3T32NT3kqoTwex2Oueck09b2Rm0Z8LE4IGD_2xMGDyO4x1Pxg6Oupn0TjoR-PU4A_Sj2RRlGDXxK5SeJO-bq63IZ3lpaQH8rzOsKsulZa7QdGuRTqbnd1tp2fnixrT7LWgKG-ZOquH3SYVmuQVZ--XfPAURKd6JZTp_RoJDojayLZqe1_1eru1Dmvry8cREVMlq8Cb6HLRyiFLXAXlFrSrpcrK0ZeR_fpU1NqtSL47LZJbUcI15GRtAoB67EmcaNovoOeqyFf_2FAUHaKzx83dKQr2oJUgdJ76K7au2C35tx91CkXD9DOSFlnPEQ_FPV-ffu-STocHeF10uGWdBhIh1vSiZaKdLghHQ5C3JAOC9LhhnRYkg5vkA6_BMq9wpJw-Arh8IpweI1wj9D4yEvf-rrKC6IXPcJsfe6QOSG9Ar5rVeRMXBKWtILvXlkVqwixQNqwgolkRmVRsZlZzFk1L0zDBslUwgbhMdpafFmUuwjTwiqd3JwZRjmzTGrkFs0rQMZ0KnHCSveQASBkanqfZnLLTKQbf4NbJnDLJG6ZwG0PvWkQy5QWW2unGXDtZh3sNzi3A4t7OMcEdd5-8q_9P0V32um1j7bOluflM3R7dnF2cro8QLfohB6g7YEXxsmBJLIozViUNP4Nxg-9zg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=POS0731%E2%80%85IDENTIFICATION+OF+AUTOANTIBODY+SIGNATURES+AND+BIOMARKERS+OF+DISEASE+ACTIVITY+IN+PATIENTS+WITH+SYSTEMIC+LUPUS+ERYTHEMATOSUS+%28SLE%29+USING+HIGH-THROUGHPUT+PROTEOMIC+MICROARRAYS&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Mak%2C+A.&rft.au=Nasir%2C+N.&rft.au=Cho%2C+J.&rft.date=2024-06-01&rft.pub=Elsevier+B.V&rft.issn=0003-4967&rft.volume=83&rft.spage=997&rft.epage=998&rft_id=info:doi/10.1136%2Fannrheumdis-2024-eular.4053&rft.externalDocID=S0003496724163819 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |